A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
AMPLITUDE
A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease
Chronic kidney disease, Nephropathy, Proteinuria
All genders
18-65
Recruiting now
Overview
Principal Investigator: Daniel Weiner, MD, MS
Contact Us
Katie Ferguson
Study details
Inclusion Criteria
- Age 18-65
- Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex-designated investigational clinical study assay.
Exclusion Criteria
- History of organ / bone marrow transplantation
- Diagnosis of Diabetes Mellitus
- History of human immunodeficiency virus (HIV), hepatitis B (HBV) infection, or hepatitis C (HCV) infection.
Study Requirements
This study will last approximately 2 years. Patients will have visits approximateley every 4 weeks, blood drawn, ECGs taken, and vitals taken. Home health visits available.
If you aren't sure if you qualify, please call us and we will help determine your eligibility.